Amprion has been awarded a $100,000 research grant to support studies on the causes of sporadic amyotrophic lateral sclerosis (ALS) that could help diagnose and develop potential therapies for the disease. The project, led by Richard Smith, MD, state director of the Center for Neurologic Study, and Amprion’s…
AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the development of AS-241, an investigational treatment strategy for amyotrophic lateral sclerosis (ALS) and related diseases. AS-241 is an antisense oligonucleotide (ASO), a type of small molecule that binds to RNA…
Treatment with Qalsody (tofersen) substantially slowed disease progression and reduced markers of nerve damage in people with amyotrophic lateral sclerosis (ALS) associated with SOD1 mutations (SOD1-ALS) who took part in an expanded access program in Germany. Patient-reported outcome measures also suggested a favorable perception of Qalsody, with most…
The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech, has developed a comprehensive resource designed to help people with amyotrophic lateral sclerosis (ALS) find ongoing clinical trials applicable to their condition and location. Dubbed the ALS Trial Navigator, the new tool uses mapping technology from Esri,…
Biotechnology company ProJenX has received a $1 million grant from the ALS Association to support a portion of an ongoing clinical trial, which will test prosetin in people with amyotrophic lateral sclerosis (ALS). The PRO-101 Phase 1 trial (NCT05279755) is testing prosetin in three parts. The…
BrainStorm Cell Therapeutics has reached an alignment with the U.S. Food and Drug Administration (FDA) on the chemistry, manufacturing, and controls aspects — known as CMC — of the company’s upcoming Phase 3b trial of NurOwn (debamestrocel), to be tested in people with amyotrophic lateral sclerosis (ALS). This…
Tiziana Life Sciences has applied for a grant from the ALS Association to fund an early-stage clinical trial testing intranasal foralumab as a potential therapy for amyotrophic lateral sclerosis (ALS). The association invited the company to apply for the grant, which is offered under the Hoffman…
Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) that’s designed to restore UNC13A function in nerve cells. UNC13A is an essential regulator of neurotransmitter release at synapses, a key process…
Spinogenix will soon launch a Phase 1/2 clinical trial in the U.S. to test its investigational small molecule SPG302 in people with amyotrophic lateral sclerosis (ALS). The trial, which will assess the medication’s safety, tolerability, and pharmacological properties when given as a once-daily pill, comes after The U.S.
The ALS Association has selected InnoVision Marketing Group as its agency of record for creating media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS) and the association’s mission of improving the lives of people with ALS. InnoVision, which has previously collaborated with the nonprofit on specific initiatives…
